LONA EBITDA | LeonaBio, Inc.

LeonaBio, Inc. (LONA) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$19.45M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$17.21M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$6.87M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$7.29M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$19.45M	(m)	(m)	(m)	(m)	-$16.96M*	(m)	$12.70M	(m)	(m)
2026-03-31	Reported	(m)	-$17.21M	(m)	(m)	(m)	(m)	-$20.90M	(m)	$11.26M	(m)	(m)
2025-09-30	Reported	(m)	-$6.87M	(m)	(m)	(m)	(m)	-$4.67M*	(m)	$2.83M	(m)	(m)
2025-06-30	Reported	(m)	-$7.29M	(m)	(m)	(m)	(m)	-$7.00M*	(m)	$3.66M	(m)	(m)
2025-03-31	Reported	(m)	-$9.54M	(m)	(m)	(m)	(m)	-$14.66M	(m)	$4.30M	(m)	(m)
2024-09-30	Reported	(m)	-$29.62M	(m)	(m)	(m)	$0.00*	-$23.02M*	(m)	$17.92M	(m)	(m)
2024-06-30	Reported	(m)	-$28.03M	(m)	(m)	(m)	$28.00K*	-$22.33M*	(m)	$22.15M	(m)	(m)
2024-03-31	Reported	(m)	-$27.69M	(m)	(m)	(m)	$5.00K	-$25.80M	(m)	$21.24M	(m)	(m)
2023-09-30	Reported	(m)	-$35.04M	(m)	(m)	(m)	$30.00K*	-$23.98M*	(m)	$27.20M	(m)	(m)
2023-06-30	Reported	(m)	-$31.64M	(m)	(m)	(m)	$33.00K*	-$24.28M*	(m)	$21.61M	(m)	(m)
2023-03-31	Reported	(m)	-$29.77M	(m)	(m)	(m)	$241.00K	-$26.19M	(m)	$21.29M	(m)	(m)
2022-09-30	Reported	(m)	-$24.13M	(m)	(m)	(m)	$244.00K*	-$21.64M*	(m)	$16.96M	(m)	(m)
2022-06-30	Reported	(m)	-$23.57M	(m)	(m)	(m)	$151.00K*	-$18.59M*	(m)	$14.80M	(m)	(m)
2022-03-31	Reported	(m)	-$23.39M	(m)	(m)	(m)	$745.00K	-$16.57M	(m)	$14.46M	(m)	(m)
2021-09-30	Reported	(m)	-$17.83M	(m)	(m)	(m)	$128.00K*	-$10.30M*	(m)	$10.71M	(m)	(m)
2021-06-30	Reported	(m)	-$16.64M	(m)	(m)	(m)	$114.00K*	-$7.32M*	(m)	$12.02M	(m)	(m)
2021-03-31	Reported	(m)	-$10.78M	(m)	(m)	(m)	$304.00K	-$7.30M	(m)	$7.45M	(m)	(m)
2020-09-30	Reported	(m)	-$7.40M	(m)	(m)	(m)	(m)	-$9.41M*	(m)	$5.83M	(m)	(m)
2020-06-30	Reported	(m)	-$2.25M	(m)	(m)	(m)	(m)	-$2.86M*	(m)	$1.68M	(m)	(m)
2020-03-31	Reported	(m)	-$1.27M	(m)	(m)	(m)	(m)	-$1.18M	(m)	$592.00K	(m)	(m)
2019-09-30	Reported	(m)	-$1.53M	(m)	(m)	(m)	(m)	(m)	(m)	$1.03M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$102.27M	(m)	(m)	(m)	(m)	-$45.73M	(m)	$17.50M	(m)	$0.00
2024-12-31	Reported	(m)	-$100.90M	(m)	(m)	(m)	$33.00K	-$97.17M	(m)	$70.68M	(m)	(m)
2023-12-31	Reported	(m)	-$125.47M	(m)	(m)	(m)	$304.00K	-$100.75M	(m)	$93.79M	(m)	(m)
2022-12-31	Reported	(m)	-$104.02M	(m)	(m)	(m)	$1.14M	-$72.47M	(m)	$61.46M	(m)	(m)
2021-12-31	Reported	(m)	-$64.02M	(m)	(m)	(m)	$1.57M	-$43.10M	(m)	$42.79M	(m)	(m)
2020-12-31	Reported	(m)	-$20.00M	(m)	(m)	(m)	$2.32M	-$24.11M	(m)	$13.29M	(m)	(m)
2019-12-31	Reported	(m)	-$5.45M	(m)	(m)	(m)	(m)	-$3.71M	(m)	$3.79M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Instil Bio, Inc. (TIL)	United States	$0.048B	-1.73
Tevogen Inc. (TVGN)	United States	$0.049B
Metagenomi Therapeutics, Inc. (MGX)	United States	$0.044B	-0.48
Scilex Holding Co (SCLX)	United States	$0.042B	-0.14
Inmune Bio, Inc. (INMB)	United States	$0.056B	-2.48
ImageneBio, Inc. (IMA)	United States	$0.056B	-1.31
BioAtla, Inc. (BCAB)	United States	$0.058B	-0.21
EXOZYMES INC. (EXOZ)	United States	$0.058B
aTYR PHARMA INC (ATYR)	United States	$0.033B	-0.98
MiNK Therapeutics, Inc. (INKT)	United States	$0.063B	-5.37